Your browser doesn't support javascript.
loading
Zika virus cleaves GSDMD to disseminate prognosticable and controllable oncolysis in a human glioblastoma cell model.
Kao, Yu-Ting; Wang, Hsin-I; Shie, Chi-Ting; Lin, Chiou-Feng; Lai, Michael M C; Yu, Chia-Yi.
Affiliation
  • Kao YT; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 350, Taiwan.
  • Wang HI; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 350, Taiwan.
  • Shie CT; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 350, Taiwan.
  • Lin CF; Department of Microbiology and Immunology, Taipei Medical University, Taipei 110, Taiwan.
  • Lai MMC; Research Center for Emerging Viruses, China Medical University Hospital, Taichung 404, Taiwan.
  • Yu CY; Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.
Mol Ther Oncolytics ; 28: 104-117, 2023 Mar 16.
Article de En | MEDLINE | ID: mdl-36699618
ABSTRACT
Glioblastoma (GBM) is the most common aggressive malignant brain cancer and is chemo- and radioresistant, with poor therapeutic outcomes. The "double-edged sword" of virus-induced cell death could be a potential solution if the oncolytic virus specifically kills cancer cells but spares normal ones. Zika virus (ZIKV) has been defined as a prospective oncolytic virus by selectively targeting GBM cells, but unclear understanding of how ZIKV kills GBM and the consequences hinders its application. Here, we found that the cellular gasdermin D (GSDMD) is required for the efficient death of a human GBM cell line caused by ZIKV infection. The ZIKV protease specifically cleaves human GSDMD to activate caspase-independent pyroptosis, harming both viral protease-harboring and naive neighboring cells. Analyzing human GSDMD variants showed that most people were susceptible to ZIKV-induced cytotoxicity, except for those with variants that resisted ZIKV cleavage or were defective in oligomerizing the N terminus GSDMD cleavage product. Consistently, ZIKV-induced secretion of the pro-inflammatory cytokine interleukin-1ß and cytolytic activity were both stopped by a small-molecule inhibitor targeting GSDMD oligomerization. Thus, potential ZIKV oncolytic therapy for GBM would depend on the patient's GSDMD genetic background and could be abolished by GSDMD inhibitors if required.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Mol Ther Oncolytics Année: 2023 Type de document: Article Pays d'affiliation: Taïwan

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Mol Ther Oncolytics Année: 2023 Type de document: Article Pays d'affiliation: Taïwan